> DBV Technologies revealed it expects to compile the information needed to resubmit a filing for approval of its peanut allergy drug in the third quarter. Shares in DBV rose 13% following the news. Statement
> Exscientia named Andrew Douglas as its director of data engineering. Release
> The British Library struck a property development deal that will create life sciences laboratory and office space in London. Statement (PDF)
> Summit Therapeutics dosed the first patient in a phase 3 trial of its treatment for Clostridium difficile infection. Top-line data are due in the second half of 2021. Release (PDF)
> ADC Therapeutics dosed the first patient in a phase 1 trial that is testing its anti-CD19 antibody-drug conjugate in combination with AstraZeneca’s Imfinzi. Statement
> Markus Dangl joined Achilles Therapeutics as CSO. Dangl worked at Medigene and Roche earlier in his career. Release